Today, we’re joined by Mark O'Connor, a pioneer in the field of oncology R&D, whose work has significantly impacted the way we approach cancer treatment. With over 30 years of experience, our guest serves as Chief Scientist in AstraZeneca’s Oncology R&D division, providing scientific leadership to a team of more than 150 researchers. Specializing in DNA damage response (DDR) biology, he has been instrumental in the discovery and development of groundbreaking cancer therapies, including olaparib (Lynparza), the first-in-class PARP inhibitor approved for clinical use.

In this episode, we delve into his remarkable journey—from earning a Ph.D. in Biochemistry at Bristol University to conducting postdoctoral research in Singapore, and ultimately leading the development of AstraZeneca’s industry-leading DDR pipeline. He shares insights from his time at the Cambridge start-up KuDOS, which laid the foundation for the success of Lynparza. We also discuss his commitment to building global collaborations and driving innovation that translates scientific discoveries into life-changing medicines for patients.

Tune in for a fascinating conversation about scientific leadership, the future of oncology R&D, and how a lifelong passion for advancing cancer care has shaped his life and career.